Several lines of evidence suggest that mutant huntingtin affects gene transcription by sequestering transcription activating and repressing proteins. This does not explain the gene expression changes that occur before mutant huntingtin is detectable in the nucleus, nor does it account for transcription changes caused by abnormal signaling from damaged afferent neurons. The overall aim of this application is to test the hypothesis that the earliest gene expression changes in Huntington's disease (HD) reflect a response of the neuron to misfolded huntingtin protein and to abnormal signaling between afferent and target neurons. To accomplish this the investigator proposes two Specific Aims 1) use mice and cell culture models that express mutant huntingtin protein in eitherthe nucleus orthe cytoplasm to determine how cells transcriptionally respond to each and 2) use mice that express mutant huntingtin protein in eitherafferent neurons ortarget neurons to determine transcriptional responses in neurons. The transcriptional responses will be correlated with pathogenic changes that occur in response to the transgenes. This will generate information and tools needed to further model and test early processes in Huntington's disease. Our long-term goal is to identify early pathogenic events in Huntington's disease in order to provide rational targets for the development of prophylactic drugs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS042157-02
Application #
6530003
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (02))
Program Officer
Oliver, Eugene J
Project Start
2001-08-15
Project End
2005-07-31
Budget Start
2002-08-01
Budget End
2003-07-31
Support Year
2
Fiscal Year
2002
Total Cost
$432,500
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
Reynolds, Matthew R; Kamath, Ashwin A; Grubb, Robert L et al. (2014) The safety of aeroplane travel in patients with symptomatic carotid occlusion. J Neurol Neurosurg Psychiatry 85:435-7
Powers, William J; Clarke, William R; Grubb Jr, Robert L et al. (2014) Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia. Neurology 82:1027-32
Grubb Jr, Robert L; Powers, William J; Clarke, William R et al. (2013) Surgical results of the Carotid Occlusion Surgery Study. J Neurosurg 118:25-33
Powers, William J (2012) Letter by Powers Regarding Article, ""Failure of cerebral hemodynamic selection in general or of specific positron emission tomography methodology? Carotid occlusion surgery study (COSS)"". Stroke 43:e43
Powers, William J; Clarke, William R; Grubb Jr, Robert L et al. (2011) Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 306:1983-92
Strand, Andrew D; Aragaki, Aaron K; Baquet, Zachary C et al. (2007) Conservation of regional gene expression in mouse and human brain. PLoS Genet 3:e59
Strand, Andrew D; Baquet, Zachary C; Aragaki, Aaron K et al. (2007) Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci 27:11758-68
Rockabrand, Erica; Slepko, Natalia; Pantalone, Antonello et al. (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16:61-77
Apostol, Barbara L; Illes, Katalin; Pallos, Judit et al. (2006) Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. Hum Mol Genet 15:273-85
Strand, Andrew D; Aragaki, Aaron K; Shaw, Dennis et al. (2005) Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet 14:1863-76

Showing the most recent 10 out of 19 publications